A study assessing sulfonylureas and DPP-4 inhibitors' effect on cardiovascular outcomes showed no significant (hazard ratio (HR) 0.95 [0.80-1.14]; 95% CI; p= 0.604) difference in overall MACEs (including myocardial infarction, stroke, unstable angina, and hospitalization due to other cardiovascular causes) in patients with type 2 diabetes [6]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.